95results about How to "Reduce clinical dosage" patented technology

A Chinese medicine in the form of tablet, capsule, particle, or oral liquid for treating cardiovascular and cerebrovascular diseases is prepared from 16 Chinese-medicinal materials including Chuan-xiong rhizome, Chinese angelica root, red peony root, astragalus root, etc. Its preparing process is also disclosed.

The invention relates to preparation and application of a novel targeting peptide for specifically inhibiting tumor cell metastasis. The preparation method disclosed by the invention is technically characterized in that a polypeptide TMTP1-GG-D(KLAKLAK)2 which can simultaneously identify high metastasis potential tumor cells and inhibit tumor cell growth and metastasis is prepared, and antimicrobial peptides can be specifically transported into malignant tumor tissues and local metastasis through the polypeptide, so that the high metastasis potential tumor cells can be selectively killed, an obvious toxic or side effect is avoided, the tumor growth and metastasis are effectively inhibited, the polypeptide is expected to become a novel antitumor medicine, and the key defects in the conventional tumor molecule targeted therapy technology and practice can be overcome. The invention aims to provide the polypeptide which can simultaneously and specifically identify and restrict tumor cells with high metastasis potential tendency, so that the problems of large side effects, low specificity and the like existing in existing targeting medicines are solved, highly-efficient and specific tumor inhibiting and killing effects are expected to be achieved in clinical treatment, and the treatment aim of greatly killing the tumor cells in a targeted mode can be furthest achieved due to the novel polypeptide. In addition, the invention also can provide a novel design mode for subsequent other molecular therapy.

The invention discloses tetanus toxin T cell epi position peptide and human B lymphocyte activate and gene interfusing albumen. It could activate CD4⁺T cell to take cell action, promote body liquid immunity level. It adopts step clone to construct TT and BLyS interfusing gene and gain high efficiency expression in coliform bacteria. It conquers the immunity tolerate of the body.

The present invention provides a combined pharmaceutical composition of paclitaxel and CDKS kinase inhibitors, comprising active ingredients and pharmaceutically acceptable excipients, characterized in that: the active ingredients are composed of paclitaxel and CDK4/6 kinase represented by formula I Inhibitors or pharmaceutically acceptable salts thereof, the mass ratio of paclitaxel and CDK4/6 kinase inhibitors or pharmaceutically acceptable salts thereof in the active ingredient is (2‑8):1. The pharmaceutical composition has good anticancer curative effect and low toxic and side effects; due to the sensitivity of CDK4/6 kinase inhibitors to paclitaxel, the combination of the two produces a synergistic effect, thereby reducing the clinical dosage of capecitabine and reducing the large dosage Toxic and side effects produced by using capecitabine can improve the safety index of clinical treatment and have good clinical application prospects.

The invention provides a medicament for preventing and treating neurologic damage and related diseases thereof, and in particular relates to the application of a neurotrophic factor mixture secreted by adult stem cells from fat or an adult stem cell in vitro culture from the fat in preventing and/or treating the neurologic damage and the related diseases thereof. The neurotrophic factor mixture exists in the cell in vitro culture; the neurotrophic factor mixture and the cell in vitro culture can generate a synergistic effect, which reinforces activity greatly, reduces clinical dose obviously, reduces treating cost and reduces side effects; and the medicament can be effectively used for the neurologic damage and the related diseases thereof, such as preventing and/or treating the anoxic ischemic encephalopathy without processing steps such as further extracting, purifying and the like or adding a carrier, which fills the gap of the deficiency of conventional preventing and treating means for the neurologic damage and the related diseases thereof, simultaneously reduces the side effects and untoward effects, and further contributes to the reduction of the production cost of the medicament and popularization and application.

A Chinese medicine for treating cardiovascular and cerebrovascular diseases is prepared from red peony root and capejasmine fruit. The prescription and preparing process of its injection and its other clinical forms are also disclosed.

The invention provides a eucalyptus oil doxycycline hydrochloride self-microemulsion g for livestock and a preparation method and application of the eucalyptus oil doxycycline hydrochloride self-microemulsifon. The self-microemulsion comprises the following components in proportion of 50-250 g/L of doxycycline hydrochloride raw drugs, 1-50 g/L of a solvent, 0.1-2 g/L of an antioxidant, 80-300 g/La surfactant, 60-300 g/L an assistance surfactant, and 100-450 g/L of an oil phase. The self-microemulsion is good in stability, uniform in particle size distribution, and good in dispersibility. Eucalyptus oil is used as the oil phase of a phase converting method, and the problem of dissolving of folium eucalypti essential oil is solved. Besides, the eucalyptus oil has mild stimulation effects onrespiratory tract nasal cavity and endotracheal mucosa, can promote mucus secretion and can dredge logged nasal cavity and logged bronchus. In addition, the self-microemulsion is simple in preparation method, mild in condition, and low in production cost, can be used for preparing medicines or feed additives for livestock, and has high economic value and biology promotion value.

The invention discloses a preparation method of stem cell factor liposome for repairing damaged tissues. The preparation method comprises the following steps: step 1, separating and culturing canine adipose-derived mesenchymal stem cells; 2, digesting the cultured canine adipose tissue-derived stromal cells, crushing, centrifuging, filtering and carrying out ultrafiltration to obtain a stem cell extracting solution; step 3, mixing the lipidosome prepared in advance with the stem cell extracting solution; carrying out ultrasonic treatment to obtain a stem cell factor liposome suspension, addingsodium propionate, uniformly mixing, and filtering to obtain stem cell factor liposome solution. The method has the advantages that the absorption rate of the stem cell factors can be increased, theactivity of the stem cell factors can be protected, the loss of effective components can be reduced, and the utilization rate of the effective components can be effectively increased. Meanwhile, the invention also discloses the stem cell factor liposome for repairing damaged tissues, which is prepared by the method, and stem cell factors in the preparation are pure natural components, so that thepreparation is safe to apply, free from toxic and side effects, free from drug residues, high in activity, small in clinical dosage and quick to take effect.

The invention provides composition for treating enterovirus infection and a drug combination method and particularly provides composition for inhibiting enteroviruses. The composition comprises a first active ingredient and a second active ingredient, wherein the first active ingredient is a 3D protein inhibitor of enterovirueses such as EV71, and the second active ingredient is a capsid protein inhibitor of enteroviruses such as EV71. Experimental results show that the pharmaceutical composition has a remarkable synergistic function, and cytotoxicity of the composition in detected combination concentration is not enhanced.

The invention provides antitumor pharmaceutic preparation composition which is prepared from IRF-beta and an IDO inhibitor or the IFN-beta and a AhR inhibitor. The antitumor pharmaceutic preparation composition can kill differential tumor cells and also can kill dormant tumor cells and has an effect of completely eliminating tumor cells.

The invention provides a new application of dracorhodin A, including an application of dracorhodin A in preparation of hypoglycemic drugs, health-care products or functional foods, and further including an application of dracorhodin A in preparation of an alpha-glucosidase activity inhibitor. The application creatively finds that dracorhodin A can inhibit the activity of alpha-glucosidase, and theinhibitory activity of dracorhodin A is far higher than that of acarbose serving as a clinical drug. The invention also provides a hypoglycemic composition, which comprises dracorhodin A and pharmaceutic adjuvants or health-care product adjuvants, and is used as a pharmaceutical preparation or a health-care product preparation.

The invention provides a composition and application thereof, and particularly provides a composition for decreasing blood sugar. The composition contains a first active component with berberine being an effective component and a second active component with timosaponin being the effective component; moreover, the effective component ratio V1 (mg: mg) of the first active component to the second active component is (1.5-6): 1. The composition can fast and effectively decrease the blood sugar and the drug feeding dose of the composition can be remarkably lowered at the same time, and adverse reactions of drugs can be reduced and a safe window is expanded.

The present invention discloses synergistic effects and applications of a series of compositions comprising magnolol, honokiol and a nonsteroidal antiinflammatory drug, wherein the chemical formulas of magnolol and honokiol are represented by a formula (I), and the chemical formula of the nonsteroidal antiinflammatory drug is represented by a formula (II). The invention further relates to applications of the compositions in anti-inflammatory drugs, drugs for skin, cosmetic protection, and other fields. The formulas I and II are defined in the specification.

The invention relates to the technical field of medical biological detection, and provides an application of rattlerin in preparing an anti-fungal drug sensitizer, an anti-fungal drug sensitizer taking rattlerin as an active ingredient and an anti-fungal combination preparation. According to experimental measurement, when fluconazole and rattlerin are combined, FICI of all experimental strains isless than or equal to 0.50, so that a strong synergistic effect is shown, meanwhile, the MIC value of fluconazole is decreased by 2-16 times, the sensitivity of fluconazole to cryptococcus is improved, so that the rattlerin not only is beneficial to reducing clinical dosage, but also is beneficial to slowing down the phenomenon of high drug resistance rate of cryptococcus, and conducts beneficialexploration for clinical anti-fungal infection.

The invention provides a drug composition for synergistically resisting a pancreatic cancer. The drug includes an active component and a pharmaceutically acceptable auxiliary material and is characterized in that the active component includes gemcitabine and a triterpenoid; and the triterpenoid is 3 alpha, 11 alpha-dihydroxy-lupin-20(29)-ene-28-acid or 3 alpha-hydroxy-lupin-20(29)-ene-23, 28-diacid. According to the drug composition, the synergistic effect of combined medication to pancreatic cancer cells is judged on various aspects of a pancreatic cancer cell growth state, a cell growth inhibition percentage, influences of cell cycle and apoptosis and the like; and due to the drug resistance of the gemcitabine, by adopting combined medication, more medication safety is provided, clinic use dosage of the gemcitabine is lowered, the toxic and side effects generated by using a large dosage of the gemcitabine are reduced, the clinic treatment safety index is improved, and more possibilities are provided for clinic application of the gemcitabine.

The invention belongs to the technical field of medicaments, in particular relates to a benzocyclodirivative as shown in a general formula (I) as well as pharmaceutically acceptable salts, a hydras and an isomer thereof, wherein R1, R2, R3, R4, Q, X and Y are defined in the specification. The invention also relates to a preparation method of the compounds, a pharmaceutical composition containing the compounds and application of the compounds in preparing medicaments for treating and/or preventing non-insulin-dependent diabetes mellitus.